Concepts (135)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Breast Neoplasms | 11 | 2022 | 667 | 4.410 |
Why?
|
| Receptor, erbB-2 | 7 | 2022 | 45 | 3.010 |
Why?
|
| Carcinoma, Ductal, Breast | 3 | 2019 | 28 | 1.840 |
Why?
|
| Carcinoma, Lobular | 3 | 2019 | 12 | 1.830 |
Why?
|
| Breast | 4 | 2017 | 53 | 1.410 |
Why?
|
| Immunohistochemistry | 3 | 2017 | 519 | 1.210 |
Why?
|
| Fibrocystic Breast Disease | 2 | 2016 | 2 | 1.140 |
Why?
|
| Carcinoma, Intraductal, Noninfiltrating | 2 | 2016 | 17 | 1.120 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2018 | 337 | 1.050 |
Why?
|
| Cytodiagnosis | 3 | 2020 | 16 | 0.940 |
Why?
|
| Aged, 80 and over | 10 | 2019 | 3728 | 0.900 |
Why?
|
| Neoplasms, Adnexal and Skin Appendage | 1 | 2022 | 2 | 0.840 |
Why?
|
| Adnexal Diseases | 1 | 2022 | 6 | 0.840 |
Why?
|
| Adenoma | 1 | 2022 | 35 | 0.810 |
Why?
|
| Adult | 14 | 2020 | 8468 | 0.810 |
Why?
|
| Female | 19 | 2022 | 18241 | 0.800 |
Why?
|
| Middle Aged | 15 | 2020 | 10872 | 0.800 |
Why?
|
| Aged | 14 | 2020 | 9515 | 0.780 |
Why?
|
| Molecular Diagnostic Techniques | 2 | 2017 | 9 | 0.770 |
Why?
|
| Thyroid Neoplasms | 2 | 2020 | 28 | 0.750 |
Why?
|
| Carcinoma, Neuroendocrine | 1 | 2020 | 13 | 0.730 |
Why?
|
| Mixed Tumor, Mullerian | 1 | 2019 | 1 | 0.720 |
Why?
|
| Adenocarcinoma, Clear Cell | 1 | 2019 | 2 | 0.720 |
Why?
|
| Carcinoma, Endometrioid | 1 | 2019 | 4 | 0.720 |
Why?
|
| Fallopian Tube Neoplasms | 1 | 2019 | 7 | 0.720 |
Why?
|
| Neoplastic Syndromes, Hereditary | 1 | 2019 | 3 | 0.680 |
Why?
|
| Breast Neoplasms, Male | 1 | 2018 | 11 | 0.670 |
Why?
|
| Ovarian Neoplasms | 1 | 2019 | 87 | 0.670 |
Why?
|
| Humans | 21 | 2022 | 29220 | 0.650 |
Why?
|
| Genetic Heterogeneity | 1 | 2017 | 13 | 0.620 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2018 | 91 | 0.620 |
Why?
|
| GATA3 Transcription Factor | 1 | 2017 | 2 | 0.610 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2017 | 401 | 0.610 |
Why?
|
| Adenocarcinoma, Mucinous | 1 | 2017 | 20 | 0.610 |
Why?
|
| In Situ Hybridization | 1 | 2017 | 35 | 0.590 |
Why?
|
| Head and Neck Neoplasms | 2 | 2016 | 117 | 0.590 |
Why?
|
| Neoplasms, Second Primary | 1 | 2016 | 16 | 0.580 |
Why?
|
| Carcinoma | 2 | 2016 | 87 | 0.580 |
Why?
|
| Precancerous Conditions | 1 | 2016 | 24 | 0.570 |
Why?
|
| Colorectal Neoplasms | 1 | 2019 | 208 | 0.570 |
Why?
|
| Peritoneal Neoplasms | 1 | 2019 | 241 | 0.570 |
Why?
|
| Sentinel Lymph Node Biopsy | 1 | 2016 | 69 | 0.560 |
Why?
|
| Carcinoma in Situ | 1 | 2016 | 13 | 0.560 |
Why?
|
| Cicatrix | 1 | 2016 | 36 | 0.540 |
Why?
|
| Neoplasm Metastasis | 1 | 2016 | 199 | 0.540 |
Why?
|
| Receptors, Estrogen | 3 | 2022 | 89 | 0.520 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2016 | 142 | 0.520 |
Why?
|
| Adenocarcinoma | 1 | 2017 | 301 | 0.490 |
Why?
|
| Receptors, Progesterone | 3 | 2019 | 45 | 0.460 |
Why?
|
| Brain Neoplasms | 1 | 2019 | 587 | 0.450 |
Why?
|
| Prognosis | 3 | 2022 | 1363 | 0.430 |
Why?
|
| I-kappa B Kinase | 1 | 2008 | 7 | 0.340 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 2 | 2019 | 9 | 0.330 |
Why?
|
| Gene Expression Regulation, Developmental | 1 | 2008 | 68 | 0.330 |
Why?
|
| NF-kappa B | 1 | 2008 | 75 | 0.330 |
Why?
|
| Biopsy, Fine-Needle | 3 | 2016 | 50 | 0.320 |
Why?
|
| Neovascularization, Physiologic | 1 | 2008 | 106 | 0.320 |
Why?
|
| Neoadjuvant Therapy | 2 | 2017 | 56 | 0.300 |
Why?
|
| Mastectomy | 2 | 2017 | 59 | 0.300 |
Why?
|
| Hyperplasia | 2 | 2016 | 38 | 0.280 |
Why?
|
| Treatment Outcome | 3 | 2017 | 3108 | 0.260 |
Why?
|
| Signal Transduction | 1 | 2008 | 667 | 0.250 |
Why?
|
| Young Adult | 3 | 2020 | 2413 | 0.220 |
Why?
|
| Follow-Up Studies | 2 | 2019 | 2114 | 0.220 |
Why?
|
| Proteomics | 1 | 2022 | 92 | 0.200 |
Why?
|
| Extraembryonic Membranes | 1 | 2020 | 4 | 0.200 |
Why?
|
| Polyps | 1 | 2020 | 8 | 0.190 |
Why?
|
| Diagnosis, Differential | 2 | 2020 | 493 | 0.190 |
Why?
|
| Uterine Diseases | 1 | 2020 | 15 | 0.190 |
Why?
|
| Colposcopy | 1 | 2020 | 4 | 0.190 |
Why?
|
| Uterine Cervical Dysplasia | 1 | 2020 | 2 | 0.190 |
Why?
|
| Vaginal Smears | 1 | 2020 | 9 | 0.190 |
Why?
|
| Curettage | 1 | 2020 | 9 | 0.190 |
Why?
|
| Paraganglioma | 1 | 2020 | 5 | 0.190 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2020 | 32 | 0.180 |
Why?
|
| Fallopian Tubes | 1 | 2019 | 5 | 0.180 |
Why?
|
| Pregnancy Complications | 1 | 2020 | 80 | 0.180 |
Why?
|
| Peritoneum | 1 | 2019 | 24 | 0.180 |
Why?
|
| Risk Factors | 2 | 2018 | 3550 | 0.180 |
Why?
|
| Ovary | 1 | 2019 | 54 | 0.170 |
Why?
|
| Pelvis | 1 | 2019 | 61 | 0.170 |
Why?
|
| Neoplasm Invasiveness | 2 | 2017 | 189 | 0.170 |
Why?
|
| Neoplasm Staging | 1 | 2019 | 437 | 0.160 |
Why?
|
| Lymphatic Metastasis | 2 | 2016 | 156 | 0.160 |
Why?
|
| Mastectomy, Segmental | 1 | 2017 | 23 | 0.150 |
Why?
|
| Membrane Transport Proteins | 1 | 2017 | 34 | 0.150 |
Why?
|
| Glycoproteins | 1 | 2017 | 34 | 0.150 |
Why?
|
| Gene Amplification | 1 | 2017 | 9 | 0.150 |
Why?
|
| Genes, erbB-2 | 1 | 2017 | 5 | 0.150 |
Why?
|
| Lymph Nodes | 1 | 2017 | 92 | 0.150 |
Why?
|
| Gene Dosage | 1 | 2017 | 34 | 0.150 |
Why?
|
| Genomics | 1 | 2017 | 82 | 0.150 |
Why?
|
| Thyroid Nodule | 1 | 2016 | 5 | 0.140 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2016 | 20 | 0.140 |
Why?
|
| Papillomaviridae | 1 | 2016 | 17 | 0.140 |
Why?
|
| Mammography | 1 | 2016 | 37 | 0.140 |
Why?
|
| Carrier Proteins | 1 | 2017 | 131 | 0.140 |
Why?
|
| Neoplasm Proteins | 1 | 2016 | 141 | 0.130 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2016 | 249 | 0.130 |
Why?
|
| Gene Expression | 1 | 2016 | 332 | 0.130 |
Why?
|
| Retrospective Studies | 2 | 2020 | 3122 | 0.110 |
Why?
|
| Cohort Studies | 1 | 2017 | 1695 | 0.110 |
Why?
|
| Male | 3 | 2018 | 17876 | 0.100 |
Why?
|
| Risk Assessment | 1 | 2017 | 1313 | 0.100 |
Why?
|
| rho GTP-Binding Proteins | 1 | 2009 | 9 | 0.090 |
Why?
|
| Neoplasms, Squamous Cell | 1 | 2009 | 7 | 0.090 |
Why?
|
| Genes, Lethal | 1 | 2008 | 1 | 0.080 |
Why?
|
| Genes, Reporter | 1 | 2008 | 37 | 0.080 |
Why?
|
| Embryo, Mammalian | 1 | 2008 | 30 | 0.080 |
Why?
|
| Endothelial Cells | 1 | 2008 | 179 | 0.080 |
Why?
|
| Mice, Knockout | 1 | 2008 | 425 | 0.080 |
Why?
|
| Sensitivity and Specificity | 2 | 2020 | 533 | 0.070 |
Why?
|
| Cell Proliferation | 1 | 2008 | 573 | 0.070 |
Why?
|
| Mice | 2 | 2009 | 2372 | 0.070 |
Why?
|
| Alphapapillomavirus | 1 | 2020 | 9 | 0.050 |
Why?
|
| Cervix Uteri | 1 | 2020 | 21 | 0.050 |
Why?
|
| Pre-Eclampsia | 1 | 2020 | 53 | 0.050 |
Why?
|
| Animals | 2 | 2009 | 7302 | 0.050 |
Why?
|
| Placenta | 1 | 2020 | 63 | 0.050 |
Why?
|
| Cesarean Section | 1 | 2020 | 82 | 0.050 |
Why?
|
| Papillomavirus Infections | 1 | 2020 | 52 | 0.040 |
Why?
|
| Genotype | 1 | 2020 | 735 | 0.040 |
Why?
|
| Pregnancy | 1 | 2020 | 816 | 0.040 |
Why?
|
| Gene Expression Profiling | 1 | 2016 | 320 | 0.030 |
Why?
|
| Adolescent | 1 | 2020 | 3265 | 0.030 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2020 | 1383 | 0.030 |
Why?
|
| Mice, SCID | 1 | 2009 | 71 | 0.020 |
Why?
|
| Gene Knockdown Techniques | 1 | 2009 | 73 | 0.020 |
Why?
|
| Transfection | 1 | 2009 | 192 | 0.020 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2009 | 248 | 0.020 |
Why?
|
| Mice, Nude | 1 | 2009 | 276 | 0.020 |
Why?
|
| Cell Movement | 1 | 2009 | 161 | 0.020 |
Why?
|
| RNA, Messenger | 1 | 2009 | 514 | 0.020 |
Why?
|
| Cell Line, Tumor | 1 | 2009 | 681 | 0.020 |
Why?
|
| Lung Neoplasms | 1 | 2009 | 384 | 0.020 |
Why?
|